Aldeyra Therapeutics Inc (ALDX) — Institutional Investor Activity (Q2 2026)

ALDX ranks #4416 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ALDX is a disclosed holding of Cliff Asness (AQR Capital Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

ALDX is a top-conviction position for Knoll Capital Management, LLC — at 6.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

BNP Paribas Financial Markets has added to its ALDX position for two straight quarters, increasing it by $321.3K to reach $334.9K today.

BlackRock has trimmed its ALDX position for two straight quarters, cutting it by $17.3M while still holding $2.7M.

ALDX is down 0% today, but institutions show net buying of $2.6M this quarter — a divergence between today's price move and the underlying institutional flow.

ALDX reported a net loss of $33.8M in its latest fiscal year.

• Not yet profitable — net loss of $33.8M in the latest fiscal year
• Net income improved year over year, from -$55.9M to -$33.8M
• Operating cash flow was negative, using $33.3M in cash
• Current ratio of 2.58x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.63x equity — within a conventional range